Artikel ; Online: Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes.
The Journal of clinical investigation
2020 Band 130, Heft 10, Seite(n) 5223–5234
Abstract: Dengue virus (DENV) infection requires cholesterol as a proviral factor, although statin treatment did not show antiviral efficacy in patients with dengue. Here, we show that DENV infection manipulated cholesterol metabolism in cells residing in low- ... ...
Abstract | Dengue virus (DENV) infection requires cholesterol as a proviral factor, although statin treatment did not show antiviral efficacy in patients with dengue. Here, we show that DENV infection manipulated cholesterol metabolism in cells residing in low-oxygen microenvironments (hypoxia) such as in the liver, spleen, and lymph nodes. DENV infection induced expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), which reduces low-density lipoprotein receptor (LDLR) recycling and hence cholesterol uptake. We found that, whereas LDLR uptake would have distributed cholesterol throughout the various cell compartments, de novo cholesterol synthesis enriched this lipid in the endoplasmic reticulum (ER). With cholesterol enrichment in the ER, ER-resident STING and type I IFN (IFN) activation was repressed during DENV infection. Our in vitro findings were further supported by the detection of elevated plasma PCSK9 levels in patients with dengue with high viremia and increased severity of plasma leakage. Our findings therefore suggest that PCSK9 plays a hitherto unrecognized role in dengue pathogenesis and that PCSK9 inhibitors could be a suitable host-directed treatment for patients with dengue. |
---|---|
Mesh-Begriff(e) | Adolescent ; Adult ; Antiviral Agents/pharmacology ; Cell Hypoxia ; Cell Line ; Child ; Cholesterol/metabolism ; Dengue/drug therapy ; Dengue/etiology ; Dengue/metabolism ; Dengue Virus/pathogenicity ; Drug Resistance, Viral ; Female ; Hepatocytes/metabolism ; Hepatocytes/virology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology ; Male ; Myeloid Cells/metabolism ; Myeloid Cells/virology ; Proprotein Convertase 9/blood ; Proprotein Convertase 9/metabolism ; Receptors, LDL/metabolism ; Young Adult |
Chemische Substanzen | Antiviral Agents ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; LDLR protein, human ; Receptors, LDL ; Cholesterol (97C5T2UQ7J) ; PCSK9 protein, human (EC 3.4.21.-) ; Proprotein Convertase 9 (EC 3.4.21.-) |
Sprache | Englisch |
Erscheinungsdatum | 2020-08-24 |
Erscheinungsland | United States |
Dokumenttyp | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 3067-3 |
ISSN | 1558-8238 ; 0021-9738 |
ISSN (online) | 1558-8238 |
ISSN | 0021-9738 |
DOI | 10.1172/JCI137536 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Ua VI Zs.184: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.